2023-01至今，betway体育下载 ，副研究員

2022-07至2022-12，betway体育下载 ，助理研究員

2020-07至2022-07，betway体育下载 ，博士後

2017-09至2020-06，中國科學院大學，免疫學博士

2013-08至2017-08，betway体育下载 ，研究實習員

2010-09至2013-06，揚州大學，預防獸醫學碩士

2006-09至2010-06，塔裏木大學，動物醫學學士

腫瘤免疫療法

嵌合抗原受體T細胞（CAR-T）療法

（1）國家自然科學基金-青年科學基金項目，82202031，LIGHT-HVEM通路提升CAR-T細胞抗腫瘤活性的機製研究，2023-01-01至2025-12-31，項目負責人

（2）廣東省自然科學基金-麵上項目，2214050008936，PD-L1轉換型受體T細胞增強CAR-T細胞抗腫瘤活性的機製研究, 2022-01至2024-12，項目負責人

（3）廣東省基礎與應用基礎研究基金區域聯合基金-青年基金項目，21201910240000902，靶向PD-L1的CARP T細胞提升CAR-T細胞體內維持能力的機製研究，2021-10至2024-09，項目負責人

（4）中國科學院特別研究助理資助項目，2022-01至2024-12，項目負責人

廣東省科技進步二等獎，“人源化小鼠及其臨床前評估平台的建立及應用”（2019.07.10）

(1)Le Qin; Yuanbin Cui; Tingjie Yuan; Dongmei Chen; Ruocong Zhao; Shanglin Li; Zhiwu Jiang; Qiting Wu; Youguo Long; Suna Wang; Zhaoyang Tang; Huixia Pan; Xiaoping Li; Wei Wei; Jie Yang; Xuequn Luo; Zhenfeng Zhang; Qiannan Tang; Pentao Liu; Robert Weinkove; Yao Yao; Dajiang Qin; Jean Paul Thiery; Peng Li; Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis, Nature Communications, 2022,13(1)

(2)Le Qin; Ruocong Zhao; Dongmei Chen; Xinru Wei; Qiting Wu; Youguo Long; Zhiwu Jiang; Yangqiu Li; Haipeng Wu; Xuchao Zhang; Yilong Wu; Shuzhong Cui; Wei Wei; Huihui Yao; Zixia Liu; Su Cao; Yao Yao; Zhenfeng Zhang; Peng Li; Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth, Biomarker Research, 2020, 2020(8): 0-19

(3)Le Qin#; Yunxin Lai#; Ruocong Zhao; Xinru Wei; Jianyu Weng; Peilong Lai; Baiheng Li; Simiao Lin; Suna Wang; Qiting Wu; Qiubin Liang; Yangqiu Li; Xuchao Zhang; Yilong Wu; Pentao Liu; Yao Yao; Duanqing Pei; Xin Du; PENG Li; Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells,Journal of Hematology & Oncology,2017, 10(1): 0-68

(4)Le Qin; Ruocong Zhao; Peng Li;Incorporation of functional elements enhances the antitumor capacity of CAR T cells,Experimental Hematology & Oncology, 2017, 6(28)

(5) Zhiwu Jiang#;Le Qin#; Yuou Tang#; Rui Liao; Jingxuan Shi; Bingjia He; Shanglin Li; Diwei Zheng; Yuanbin Cui; Qiting Wu; Youguo Long; Yao Yao; Zhihui Wei; Qilan Hong; Yi Wu; Yuanbang Mai; Shixue Gou; Xiaoping Li; Robert Weinkove; Sam Norton; Wei Luo; Weineng Feng; Hongsheng Zhou; Qifa Liu; Jiekai Chen; Liangxue Lai; Xinwen Chen; Duanqing Pei; Thomas Graf; Xingguo Liu; Yangqiu Li; Pentao Liu; Zhenfeng Zhang; Peng Li; Human induced-T-to-natural killer cells have potent antitumour activities, Biomark Research, 2022, 10(13)

(6) Peilong Lai#; Xiaomei Chen#;Le Qin#; Zhiwu Jiang; Chenwei Luo; Xin Huang; Sujing Wu; Wei Ling; Yulian Wang; Jinghua Wang; Chenxin Deng; Lisi Huang; Lingji Zeng; Zesheng Lu; Liye Zhong; Pengjun Liao; Minming Li; Dongmei Chen2; Suxia Geng; Ping Wu; Zhaoyang Tang; Duanqing Pei; Xin Du; Peng Li; Jianyu Weng; The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection, Leukemia, 2020, 34(10): 2790-2793

(7)Nengzhi Pang#, Jingxuan Shi#,Le Qin#, Aiming Chen#, Yuou Tang, Hainan Yang, Yufeng Huang, Qingde Wu, Xufeng Li, Bingjia He, Tianheng Li, Baoxia Liang, Jinglin Zhang, Bihui Cao, Manting Liu, Yunfei Feng, Xiaodie Ye, Xiaopei Chen, Lu Wang, Yu Tian, Hao Li, Junping Li, Hong Hu, Jingping He, Yuling Hu, Cheng Zhi, Zhaoyang Tang, Yibo Gong, Fangting Xu, Linfeng Xu, Weijun Fan, Ming Zhao, Deji Chen, Hui Lian, Lili Yang, Peng Li, Zhenfeng Zhang. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.Journal of Hematology & Oncology,2021. 14(1): 118.

(8)Weng J#, Lai P#,Qin L#, Lai Y, Jiang Z, Luo C, Huang X, Wu S, Shao D, Deng C, Huang L, Lu Z, Zhou M, Zeng L, Chen D, Wang Y, Chen X, Geng S, Robert W, Tang Z, He C, Li P, Du X. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.Journal of Hematology & Oncology. 2018. 11(1): 25.